Skip to main
EKSO

EKSO Stock Forecast & Price Target

EKSO Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ekso Bionics Holdings Inc. demonstrated strong financial recovery in the third quarter of 2025, reporting total revenues of $4.22 million, which represents a 105% increase quarter-over-quarter, alongside a notable improvement in gross margins to 60.3%. The sequential sales recovery indicates that previous challenges were likely temporary, suggesting a potential for sustained growth. Additionally, the company's strategic move to enter into a non-binding merger agreement with Applied Digital Cloud may enhance its market position and drive further expansion in both the healthcare and industrial sectors.

Bears say

The financial analysis reveals a concerning trend for Ekso Bionics Holdings, as the company's recent revenue performance fell short of expectations, leading to notable order delays from enterprise sales that negatively impacted topline growth by $1.5 million. Additionally, the company reported a net loss of $0.54 per share in the third quarter of 2025, albeit an improvement compared to consensus estimates, which indicates persistent challenges in achieving profitability. This combination of missed revenue targets and ongoing operational weaknesses has prompted analysts to downgrade the company's stock outlook, reflecting a cautious sentiment about its financial future.

EKSO has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ekso Bionics Hlds (EKSO) Forecast

Analysts have given EKSO a Strong Buy based on their latest research and market trends.

According to 2 analysts, EKSO has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ekso Bionics Hlds (EKSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.